CXChangrui Xiao

Changrui Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Changrui Xiao has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The case for long-read sequencing for the future of genomic newborn screening

    by Seth I. Berger, Laura M. Amendola, Susan Toomey, Changrui Xiao, Jonathan LoTempio, Emmanuèle Délot, Eric Vilain, Marcy Richardson, Jessie Grzybowski, Rachid Karam, et al.

  • Open Access

    An extensible laboratory information management system for data harmonization across research centers: The ICTS Dashboard

    by Charles Hadley King, Ivan De Dios, Rebekah Barrick, Seth Berger, Miguel Almalvez, Lightning Auriga, Emmanuèle C. Délot, Changrui Xiao, Jonathan LoTempio, Eric Vilain

    /Summary: Background: Collaborative research programs increasingly require infrastructure capable of integrating heterogeneous participant, sample, and experimental data while meeting evolving research needs. Existing tools, including clinical EHRs, REDCap, generic research information management systems, and bespoke database builds, were not designed to operationalize externally governed, versioned consortium data models across database structure, APIs, validation, web forms, and reproducible exports. The ICTS Dashboard, developed at the University of California, Irvine Institute for Clinical and Translational Science, fills this need by providing a general purpose research information management system. Methods: The ICTS Dashboard was built as an open-source, schema-driven platform in which database structure, server-side validation, REST APIs, web-based forms, and reproducible exports are derived from a versioned JavaScript Object Notation (JSON) Schema set. The backend is implemented in Django, Django REST Framework, and PostgreSQL; the frontend in React. We instantiate the platform with the Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Data Model and extend it with two case studies: a locally developed biobank table for biospecimen logistics, and an embedded adaptation of the RAG-HPO retrieval-augmented phenotype curation tool. Results: The ICTS Dashboard deployed at the UCI-GREGoR site supports 37 schema-derived tables and 250 documented API endpoints. It holds metadata for 2,563 participants, 1,238 families, 5,517 biobank entries, 2,593 sequenced experiments, and 289 genetic findings. It supports quarterly external data submissions regenerated directly from the database. The biobank extension adds entities the consortium does not standardize while preserving foreign-key linkage to rare disease records; the RAG-HPO module adds curator-mediated phenotype normalization against 19,389 indexed HPO terms. Both were integrated without modifying the GREGoR Data Model. Conclusion: The Dashboard’s architecture is not limited to GREGoR or to rare disease research. A version-controlled, machine-readable data model can serve not only as a data sharing standard but as the operational backbone of a research program when paired with schema-governed tooling. Any collaborative research program with a structured, versioned model can adopt the same pattern to reduce implementation overhead and improve reproducibility, harmonization, and findable, accessible, interoperable, and reusable (FAIR)-aligned data management.

  • Open Access

    Defining Features of Gabriele‐de Vries Syndrome in Adults: A Case Report and Literature Review

    by Ethan W. Hollingsworth, Changrui Xiao

    Gabriele‐de Vries syndrome (GADEVS) is a neurodevelopmental disorder caused by heterozygous pathogenic variants in the YY1 gene. Like most rare genetic syndromes, the adult manifestations of GADEVS remain poorly defined. Here, we describe the oldest patient reported to date with GADEVS—a 63‐year‐old woman with a c.1177_1179del YY1 variant, presenting with mild intellectual disability, bilateral cataracts, and early‐onset coronary artery disease. We further review the shared and unique features across all adult patients with GADEVS in the literature. Together, this case report and review aim to broaden the phenotypic spectrum of patients with GADEVS.

  • Open Access

    Kauro, a graph-based chatbot for high-fidelity information transmission conversations

    by Charles Hadley King, Rebekah Barrick, Miguel Almalvez, Kirsten Blanco, Ivan De Dios, Vincent A. Fusaro, Emmanuèle Délot, Christopher R Donohue, Seth Berger, Changrui Xiao, et al.

    Across biomedical research and care, many conversations transmit information with profound practical, ethical, and legal consequences. The process of informed consent, where individuals decide to join a study or accept clinical care, is perhaps the most consequential, yet it is also complex, labor-intensive, and variable across sites. Existing platforms for information transmission in the informed consent context largely reproduce static documents and lack reproducibility or auditability, while generative chatbots offer flexibility at the cost of stochasticity, hallucination, and regulatory risk. We present Kauro, an open-source, graph-based chatbot that encodes scripted conversations as version-controlled JavaScript Object Notation (JSON) structures, enabling deterministic traversal (ie, paths through the graph), complete audit logging, and IRB-verifiable oversight. Its modular separation of client, server, and script ensures portability across institutions. By operationalizing constraint rather than flexibility, Kauro reframes deployment of machine intelligence in biomedical communication with reproducibility and auditability, offering a scalable platform generalizable to any domain where conversations demand safety, precision, and trust.


  • Open Access

    A Zebra in Horse's Clothing: Rethinking the Diagnosis of Rare Diseases

    by Rajeev Dutta, Cathy Duong, Virginia Kimonis, Changrui Xiao

    Introduction: Rare diseases sometimes present with deceptively common symptoms, complicating diagnosis and decisions about genetic testing. While testing for rare disease offers important benefits, it also carries risks that warrant careful consideration. Methods: We review illustrative cases of rare diseases, along with current screening and diagnostic practices, to reexamine guiding principles for genetic testing. The analysis focuses on balancing clinical utility, patient‐centered care, and broader policy implications. Results: We propose a number of recommendations to guide testing, including ruling out common causes before proceeding, ensuring the presentation is atypical for other common conditions, confirming consistency with a specific, treatable rare disease entity or group, assessing patient or family capacity for informed decision‐making, and matching test invasiveness to expected diagnostic utility. Comparison with newborn screening and diagnostic testing highlights discrepancies between these principles and common practices, highlighting the difficulty of achieving consistency. Conclusions: Establishing uniform guidelines for genetic testing remains challenging, particularly given the limited knowledge surrounding rare disorders. Coordinated efforts are needed to protect patient interests, assess the utility of diagnoses across varied contexts, and ensure that both clinical practice and policy development maximize benefits while minimizing harms.


  • Open Access

    Genome sequencing reveals the impact of pseudoexons in rare genetic disease

    by Georgia Pitsava, Megan Hawley, Light Auriga, Ivan de Dios, Arthur Ko, Sofia Marmolejos, Miguel Almalvez, Ingrid Chen, Kaylee Scozzaro, Jianhua Zhao, et al.

    Introduction Advancements in sequencing technologies have significantly improved clinical genetic testing, yet the diagnostic yield remains around 30-40%. Emerging sequencing technologies are now being deployed in the clinical setting to address the remaining diagnostic gap. Methods We tested whether short-read genome sequencing could increase diagnostic yield in individuals enrolled into the UCI-GREGoR research study, who had suspected Mendelian conditions and prior inconclusive clinical genetic testing. Two other collaborative research cohorts, focused on aortopathy and dilated cardiomyopathy, consisted of individuals who were undiagnosed but had not undergone harmonized prior testing. Results We sequenced 353 families (754 participants) and found a molecular diagnosis in 54 (15.3%) of them. Of these diagnoses, 55.5% were previously missed because the causative variants were in regions not interrogated by the original testing. In 9 cases, they were deep intronic variants, 5 of which led to abnormal splicing and cryptic exon inclusion, as directly shown by RNA sequencing. All 5 of these variants had inconclusive spliceAI scores. In 26% of newly diagnosed cases, the causal variant could have been detected by exome sequencing reanalysis. Conclusion Genome sequencing overcomes multiple limitations of clinical genetic testing, such as inability to call intronic variants and technical limitations. Our findings highlight cryptic exon inclusion as a common mechanism via which deep intronic variants cause Mendelian disease. However, they also reinforce that reanalysis of exome datasets can be a fruitful approach.


  • Open Access

    De novo variants in the non-coding spliceosomal snRNA gene RNU4-2 are a frequent cause of syndromic neurodevelopmental disorders

    by Yuyang Chen, Ruebena Dawes, Hyung Chul Kim, Sarah L Stenton, Susan Walker, Alicia Ljungdahl, Jenny Lord, Vijay S Ganesh, Jialan Ma, Alexandra C Martin-Geary, et al.

    Around 60% of individuals with neurodevelopmental disorders (NDD) remain undiagnosed after comprehensive genetic testing, primarily of protein-coding genes 1 . Increasingly, large genome-sequenced cohorts are improving our ability to discover new diagnoses in the non-coding genome. Here, we identify the non-coding RNA RNU4-2 as a novel syndromic NDD gene. RNU4-2 encodes the U4 small nuclear RNA (snRNA), which is a critical component of the U4/U6.U5 tri-snRNP complex of the major spliceosome 2 . We identify an 18 bp region of RNU4-2 mapping to two structural elements in the U4/U6 snRNA duplex (the T-loop and Stem III) that is severely depleted of variation in the general population, but in which we identify heterozygous variants in 119 individuals with NDD. The vast majority of individuals (77.3%) have the same highly recurrent single base-pair insertion (n.64_65insT). We estimate that variants in this region explain 0.41% of individuals with NDD. We demonstrate that RNU4-2 is highly expressed in the developing human brain, in contrast to its contiguous counterpart RNU4-1 and other U4 homologs, supporting RNU4-2 ’s role as the primary U4 transcript in the brain. Overall, this work underscores the importance of non-coding genes in rare disorders. It will provide a diagnosis to thousands of individuals with NDD worldwide and pave the way for the development of effective treatments for these individuals.


  • Open Access

    Considerations for reporting variants in novel candidate genes identified during clinical genomic testing

    by Jessica Xiao-Ling Chong, Seth I. Berger, Samantha Baxter, Erica Smith, Changrui Xiao, Daniel G. Calame, Megan H. Hawley, E. Andres Rivera-Munoz, Stephanie DiTroia, Genomics Research to Elucidate the Genetics of Rare Diseases (GREGoR) Consortium, et al.

    Since the first novel gene discovery for a Mendelian condition was made via exome sequencing (ES), the rapid increase in the number of genes known to underlie Mendelian conditions coupled with the adoption of exome (and more recently, genome) sequencing by diagnostic testing labs has changed the landscape of genomic testing for rare disease. Specifically, many individuals suspected to have a Mendelian condition are now routinely offered clinical ES. This commonly results in a precise genetic diagnosis but frequently overlooks the identification of novel candidate genes. Such candidates are also less likely to be identified in the absence of large-scale gene discovery research programs. Accordingly, clinical laboratories have both the opportunity, and some might argue a responsibility, to contribute to novel gene discovery which should in turn increase the diagnostic yield for many conditions. However, clinical diagnostic laboratories must necessarily balance priorities for throughput, turnaround time, cost efficiency, clinician preferences, and regulatory constraints, and often do not have the infrastructure or resources to effectively participate in either clinical translational or basic genome science research efforts. For these and other reasons, many laboratories have historically refrained from broadly sharing potentially pathogenic variants in novel genes via networks like Matchmaker Exchange, much less reporting such results to ordering providers. Efforts to report such results are further complicated by a lack of guidelines for clinical reporting and interpretation of variants in novel candidate genes. Nevertheless, there are myriad benefits for many stakeholders, including patients/families, clinicians, researchers, if clinical laboratories systematically and routinely identify, share, and report novel candidate genes. To facilitate this change in practice, we developed criteria for triaging, sharing, and reporting novel candidate genes that are most likely to be promptly validated as underlying a Mendelian condition and translated to use in clinical settings.


  • Open Access

    Adults with lysosomal storage diseases in the undiagnosed diseases network

    by Changrui Xiao, Mary Koziura, Heidi Cope, Rebecca Spillman, Khoon Tan, Fuki M. Hisama, Cynthia J. Tifft, Camilo Toro

    Objectives: To review the referral and clinical characteristics of adult patients diagnosed with lysosomal storage diseases (LSD) through the Undiagnosed Diseases Network (UDN).Methods: Retrospective review of both application and evaluation records for adults admitted to the UDN with a final diagnosis of a lysosomal storage disease.Results: Ten patients were identified. Final diagnoses included late onset Tay Sachs, attenuated MPS I, MPS IIIA, MPS IIIB, and MPS IIIC. Most patients presented with neurocognitive changes. Prior to referral, all patients had been evaluated by neurology, four patients underwent phenotype specific panel testing that did not include the causative gene, and four patients had non‐diagnostic clinical exome sequencing.Conclusions: LSDs figure highly in the differential diagnosis of neurometabolic disorders in pediatric onset progressive diseases. In adults, their subtle initial presentations overlap with symptoms of more common disorders and less practitioner awareness may lead to prolonged diagnostic challenges.


  • Inherited disorders of complex lipid metabolism: A clinical review

    by Changrui Xiao, Francis Rossignol, Frédéric M. Vaz, Carlos R. Ferreira

    Over 80 human diseases have been attributed to defects in complex lipid metabolism. A majority of them have been reported recently in the setting of rapid advances in genomic technology and their increased use in clinical settings. Lipids are ubiquitous in human biology and play roles in many cellular and intercellular processes. While inborn errors in lipid metabolism can affect every organ system with many examples of genetic heterogeneity and pleiotropy, the clinical manifestations of many of these disorders can be explained based on the disruption of the metabolic pathway involved. In this review, we will discuss the physiological function of major pathways in complex lipid metabolism, including non‐lysosomal sphingolipid metabolism, acylceramide metabolism, de novo phospholipid synthesis, phospholipid remodeling, phosphatidylinositol metabolism, mitochondrial cardiolipin synthesis and remodeling, and ether lipid metabolism as well as common clinical phenotypes associated with each. Corresponding author name: Carlos R. Ferreira, carlos.ferreira@nih.gov